Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose dual therapy for refractory Helicobacter pylori infection
ChiCTR2200057248Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amoxicillin and proton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline in Helicobacter pylori infection (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Helicobacter pylori eradication rate by urea breath test. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
amoxicillinproton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200057248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057248.